Cencora
COR
317.25
+0.88
+0.28%
Cencora
US · COR
#374 by market cap
Listed 1970
317.25
+0.88
+0.28%
Live - 5344 symbols - heartbeat 72s ago
· 2026-10-08 08:27
Pre-market
317.25
0.00%
After-hours
317.25
0.00%
Overnight
317.46
+0.07%
- Market cap
- 60.54B
- P/E (TTM)i
- 23.55
- P/Bi
- 19.84
- EPSi
- 7.96
- Div yieldi
- 0.74%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on COR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.88, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.31% YoY
Margins
- Gross margin
- 3.57%
- Operating margin
- 1.22%
- Net margin
- 0.48%
Key ratios & quality
- Enterprise valuei
- 63.84B
- Altman Z-Scorei
- 4.88
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167.94B | 179.59B | 189.89B | 213.99B | 238.59B | 262.17B | 293.96B | 321.33B |
| Gross profit | 4.61B | 5.14B | 5.19B | 6.94B | 8.30B | 8.96B | 9.91B | 11.48B |
| Selling & admin expenses | 2.46B | 2.66B | 2.77B | 3.59B | 4.85B | 5.31B | 5.66B | 6.49B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.69B | 2.01B | 2.03B | 2.84B | 2.75B | 2.69B | 3.16B | 3.93B |
| Pretax profit | 1.18B | 967.11M | -5.29B | 2.22B | 2.18B | 2.16B | 2.00B | 2.26B |
| Tax | -438.47M | 112.97M | -1.89B | 677.25M | 516.52M | 428.26M | 484.70M | 690.52M |
| Net profit | 1.62B | 854.14M | -3.40B | 1.54B | 1.67B | 1.73B | 1.52B | 1.57B |
| Basic EPS | 8 | 4 | -17 | 7 | 8 | 9 | 8 | 8 |
| Diluted EPS | 7.53 | 4.04 | -16.65 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 75.45B | 80.66B | 83.73B | 85.93B | 78.36B | 84.75B |
| Gross profit | 3.06B | 2.91B | 2.95B | 3.07B | 3.59B | 3.61B |
| Selling & admin expenses | 1.60B | 1.67B | 1.75B | 1.80B | 1.98B | 2.13B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.20B | 980.24M | 945.94M | 1.02B | 1.36B | 1.21B |
| Pretax profit | 928.66M | 896.28M | -187.04M | 708.64M | 2.09B | 996.39M |
| Tax | 211.24M | 206.53M | 146.03M | 142.51M | 459.04M | 219.73M |
| Net profit | 717.42M | 689.75M | -333.07M | 566.13M | 1.63B | 776.67M |
| Basic EPS | 4 | 4 | -2 | 3 | 8 | 4 |
| Diluted EPS | 3.68 | 3.52 | -1.75 | 2.87 | 8.40 | 3.94 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 25.89B | 28.13B | 33.06B | 38.80B | 39.59B | 42.80B | 47.72B | 52.24B |
| Cash & ST investments | 2.49B | 3.37B | 4.60B | 2.55B | 3.39B | 2.59B | 3.13B | 4.36B |
| Inventory | 11.92B | 11.06B | 12.59B | 15.37B | 15.56B | 17.45B | 19.00B | 20.49B |
| Total assets | 37.67B | 39.17B | 44.27B | 57.34B | 56.56B | 62.56B | 67.10B | 76.59B |
| Total current liabilities | 27.87B | 29.58B | 33.85B | 41.36B | 43.48B | 48.83B | 54.28B | 57.82B |
| Short-term debt | 151.66M | 139.01M | 501.26M | 300.21M | 1.07B | 641.34M | 576.33M | 117.79M |
| Long-term debt | 4.16B | 4.03B | 3.62B | 6.38B | 4.63B | 4.15B | 3.81B | 7.54B |
| Total liabilities | 34,619,877,000.00 | 36,178,774,000.00 | 45,114,466,000.00 | 56,753,394,000.00 | 56,489,343,000.00 | 61,892,459,000.00 | 66,314,925,000.00 | 74,843,027,000.00 |
| Total equity | 3.05B | 2.99B | -839.64M | 584.41M | 71.27M | 666.29M | 786.74M | 1.75B |
| Retained earnings | 3.72B | 4.24B | 518.34M | 1.67B | 2.98B | 4.32B | 5.42B | 6.53B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 46.53B | 48.81B | 52.24B | 54.15B | 53.14B | 55.34B |
| Cash & ST investments | 1.98B | 2.23B | 4.36B | 1.75B | 2.18B | 2.82B |
| Inventory | 18.97B | 20.14B | 20.49B | 24.08B | 20.01B | 21.03B |
| Total assets | 71.19B | 73.96B | 76.59B | 78.36B | 81.65B | 83.81B |
| Total current liabilities | 53.33B | 53.96B | 57.82B | 59.13B | 56.13B | 59.20B |
| Short-term debt | 770.32M | 196.79M | 117.79M | 342.28M | 202.66M | 279.16M |
| Long-term debt | 7.09B | 8.04B | 7.54B | 7.58B | 12.18B | 11.44B |
| Total liabilities | 70,014,075,000.00 | 71,747,014,000.00 | 74,843,027,000.00 | 76,265,246,000.00 | 78,067,150,000.00 | 80,566,462,000.00 |
| Total equity | 1.18B | 2.21B | 1.75B | 2.10B | 3.58B | 3.24B |
| Retained earnings | 6.40B | 6.98B | 6.53B | 6.97B | 8.49B | 9.14B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.41B | 2.34B | 2.21B | 2.67B | 2.70B | 3.91B | 3.48B | 3.88B |
| Depreciation & amortization | 510.11M | 497.51M | 408.01M | 514.79M | 709.84M | 980.85M | 1.12B | 1.07B |
| Free cash flow | 1.07B | 2.03B | 1.84B | 2.23B | 2.21B | 3.45B | 3.00B | 3.21B |
| Dividends paid | -333.04M | -338.97M | -343.58M | -366.65M | -391.69M | -398.75M | -416.17M | -437.08M |
| Stock buybacks / issuance | -639.24M | -674.03M | -354.09M | -82.15M | -483.70M | -1.18B | -1.49B | -435.47M |
| Ending cash balance | 2.49B | 3.37B | 4.60B | 3.07B | 3.59B | 2.75B | 3.30B | 4.39B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.35B | 109.25M | 3.13B | -2.31B | 1.34B | 2.65B |
| Depreciation & amortization | 263.97M | 258.97M | 264.00M | 264.27M | 262.98M | 277.43M |
| Free cash flow | 3.22B | -73.97M | 2.88B | -2.42B | 1.17B | 2.43B |
| Dividends paid | -111.19M | -107.49M | -107.51M | -126.52M | -117.46M | -116.59M |
| Stock buybacks / issuance | -50.00M | 0 | 0 | 0 | 0 | -1.00B |
| Ending cash balance | 2.18B | 2.28B | 4.39B | 1.81B | 2.24B | 2.86B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 66.37 | 29.44 | -366.53 | -- | 28,805.77 | 1,124.39 | 258.42 | 144.31 |
| ROA %i | 4.54 | 2.23 | -8.17 | 3.03 | 2.98 | 2.93 | 2.33 | 2.16 |
| ROIC %i | 28.02 | 13.92 | -65.41 | -- | 30.00 | 35.72 | 31.48 | 24.74 |
| 5-year avg ROE %i | 37.97 | 41.29 | -29.87 | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.81 | 0.65 | -2.70 | 1.12 | 1.01 | 0.93 | 0.77 | 0.83 |
| FCF / sales %i | 0.64 | 1.13 | 0.97 | 1.04 | 0.92 | 1.32 | 1.02 | 1.00 |
| Current ratioi | 0.93 | 0.95 | 0.98 | 0.94 | 0.91 | 0.88 | 0.88 | 0.90 |
| Quick ratioi | 0.50 | 0.53 | 0.56 | 0.51 | 0.51 | 0.48 | 0.50 | 0.51 |
| Debt / assetsi | 11.44 | 10.65 | 9.30 | 11.66 | 10.08 | 7.65 | 6.54 | 10.00 |
| LT debt / equityi | 141.79 | 140.12 | -- | 2,858.11 | -- | 794.27 | 590.11 | 500.19 |
| Interest coveragei | 7.21 | 5.95 | -32.39 | 13.17 | 10.41 | 8.84 | 9.06 | 6.38 |
| Revenue CAGR (3Y) %i | 7.29 | 6.94 | 7.43 | 8.41 | 9.93 | 11.35 | 11.16 | 10.43 |
| Net income CAGR (3Y) %i | -- | -15.70 | -- | -2.44 | 25.70 | -- | -0.67 | -2.92 |
| FCF CAGR (3Y) %i | -33.71 | -9.17 | 20.98 | 27.51 | 2.76 | 23.41 | 10.39 | 13.27 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 161.58 | 130.60 | 144.31 | 152.25 | 115.58 | 104.34 |
| ROA %i | 2.51 | 2.70 | 2.16 | 2.20 | 3.34 | 3.33 |
| ROIC %i | 24.07 | 26.09 | 24.74 | 20.43 | 22.88 | 23.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.84 | 0.93 | 0.83 | 0.86 | 1.21 | 1.24 |
| FCF / sales %i | 1.15 | 0.36 | 1.00 | 1.11 | 0.47 | 1.22 |
| Current ratioi | 0.87 | 0.90 | 0.90 | 0.92 | 0.95 | 0.93 |
| Quick ratioi | 0.48 | 0.50 | 0.51 | 0.47 | 0.48 | 0.48 |
| Debt / assetsi | 11.03 | 11.14 | 10.00 | 10.11 | 15.17 | 13.99 |
| LT debt / equityi | 699.61 | 406.21 | 500.19 | 397.18 | 358.57 | 375.10 |
| Interest coveragei | 8.51 | 8.05 | 6.38 | 6.19 | 8.40 | 8.05 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- U.S. Healthcare Solutions is the largest reported line at 88.33% of revenue, across 4 reported segments.
- The next-largest line, International Healthcare Solutions, is a distant second at 9.06% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
U.S. Healthcare Solutions88.33%
International Healthcare Solutions9.06%
Other2.66%
Quote time 2026-10-08 08:27:49 · For reference only, not investment advice and not tailored to your situation.